2027 HIX Rate Requests, CTEV DOJ Updates, April Hospital KPIs - Tue. 6/23 HeartBeats

Research evidence excerpt

2027 HIX Rate Requests, CTEV DOJ Updates, April Hospital KPIs - Tue. 6/23 HeartBeats

h, particularly for Rx; and 3) the notion that elevated

pricing in 2026 has so far seemingly “worked” in terms of generating plan-level

margin expansion off a depressed 2025 baseline. Consumer price elasticity for the

HIX market remains top of mind, however, and with still-hefty 2027 rate requests we

wouldn’t be surprised if sticker shock fallout further depresses 2027 HIX enrollment.

CTEV issued an 8-K • CTEV’s Criminal Proceeding Resolved Without Charges:

yesterday AMC, disclosing that DOJ’s antitrust grand jury proceeding is being wound

down and the company is not under any criminal investigation. Management reiterated

its position that its solutions and data platform comply with antitrust laws. Separately, the

company received a civil investigative demand (CID) from the DOJ’s Antitrust Division

and stated that the company is fully cooperating. (CTEV 8-K Filing, 6/22/26) Link To 8-

K Filing

We’re looking forward to catching up with the company today on this • Our Take:

development and others. Nonetheless, the announcement should clear any residual

overhang on the stock that developed first in mid-May when a potential criminal

price-fixing probe was flagged by The Capitol Forum (link to headline). Outstanding

lawsuits remain, including recent developments (link, link), but we continue to believe

CTEV’s investments to grow/diversify its businesses, combined with mgmt executing

off reasonable baselines, should allow for EBITDA upside and multiple expansion

within CTEV’s “show-me” story over time.

Consultancy Kaufman Hall (KH) published • Hospitals – Kaufman Hall Apr 2026 Report:

its April 2026 National Hospital Flash Report, which includes hospital operating trends